Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5824MR)

This product GTTS-WQ5824MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9540MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ14410MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ7910MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ3489MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ3890MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ14533MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ7921MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ9575MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW